Shots:
- Zimmer Biomet has agreed to acquire Paragon 28 for $13.00/share in cash with an equity value of ~$1.1B & enterprise value of ~$1.2B. Closing is expected in H1’25
- As per the terms, shareholders will also get a non-tradeable CVR of $1/share on achieving revenue milestones, which is payable from $0 to $1 (calculated linearly) if Zimmer’s FY’26 net sales exceed $346M up to $361M
- The acquisition will strengthen Zimmer’s portfolio with Paragon 28’s leading platform technology along with pipeline in foot & ankle surgical solutions incl. deformity correction, joint replacement, fracture & trauma
Ref: Prnewswire | Image: Paragon 28
Related News:- Zimmer Biomet Reports the Acquisition of OrthoGrid Systems
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
